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ABSTRACT
INTRODUCTION:
Deficiency or absence of factor VIII or factor IX causes hemophilia A
and hemophilia B respectively. According to the level of factor VIII
hemophilia is classified into mild, moderate and severe forms. Recent
problem in treating patients with hemophilia is development of
alloantibodies against factor VIII or IX, also known as inhibitors. This
should be suspected if the patient is not responding to replacement of
missing factor at therapeutic doses. The objective of the study was to
study the prevalence of inhibitors in severe hemophilia patients by using
Bethesda assay.
METHODOLOGY:
This was an observational study. 50 patients with severe hemophilia were
selected based on their factor levels. Among them, Hemophilia A
contributed to 36 patients, whereas 14 patients had Hemophilia B.
Inhibitor assay was done using Bethesda assay. Inhibitor development
was analyzed by comparing the various factors which influence the
development of inhibitors.
RESULTS AND DISCUSSION:
Among the patients with severe hemophilia A, 31% had inhibitors, of
which 25% had high responding inhibitors and 6% had low responding
inhibitors. Among the severe hemophilia B patients, 7% had inhibitors.
Small sample size may be a reason for the high prevalence noted in our
study.
The Mean age of patients with inhibitors and without inhibitors was
19.33 years and 23.63 years respectively. Patients with more than 30
cumulative exposure days to factor concentrates had 53% more risk of
developing inhibitors. Patients who were diagnosed earlier and those with
family history of inhibitors had significantly higher risk of developing
inhibitors during the course of treatment. Patients with inhibitors also had
a high bleeding score.
KEY WORDS:
Hemophilia, factor VIII, Bethesda assay, factor IX, inhibitors
INTRODUCTION
Hemophilia is a hereditary disorder of coagulation due to
deficiency of Factor VIII or Factor IX. Inherited as X-linked Recessive
pattern. Hemophilia A is due to mutations in the F8 Gene . Inversion of
intron 22 sequence is the most common hemophilia A mutation.
Hemophilia B is due to mutations in F9 gene.
Classification:
Based on the level of Factor VIII or IX Hemophilia are classified
into three categories
1. Mild - Factor level is 6-30%
2. Moderate – Factor level is 1-5%
3. Severe - Factor level is < 1%
Clinical features:
In the severe and moderate forms, the disease is characterized by
spontaneous or trauma related bleeding into the large joints or muscles. In
mild disease the patient experiences infrequent Bleeding especially after
trauma. If the Factor VIII or IX level is >25% the disease is diagnosed
only during routine preoperative screening tests or after major trauma.
Diagnosis:
Coagulation profile shows only an isolated prolongation of activated
Partial Thromboplastin Time.
Figure 1:  Coagulation cascade
Persons with Hemophilia(PWH) have normal platelet counts and bleeding
times. Specific determination of FVIII or FIX level is essential for
diagnosis.
Treatment:
Replacement of the missing Factor (FVIII or FIX Concentrates) is the
treatment for bleeding hemophiliacs.
The major complication of hemophilia is development of alloantibodies
to FVIII  or  FIX. Prevalence rate is 5-10% of all cases and 20% of
severe hemophilia A Patients .Only 3-5% of hemophilia B patients
detected to have inhibitors. Here we studied the prevalence of inhibitors
in persons with severe hemophilia who have had exposures to FVIII or
FIX concentrates.
OBJECTIVES
1. To detect the prevalence of inhibitors in patients with severe
hemophilia by using Bethesda assay.
2. To correlate the prevalence of inhibitors with degree of factor
exposure.
REVIEW OF LITERATURE
Historical perspective:
Hemophilia has been reported in Jewish writings as early as the
second century .The earliest attempt to treat hemophilia was done by
replacing the factors with blood plasma taken from cows and pigs. Even
though blood transfusion was used as an option for treatment since 1840,
the rational of this usage was understood only a century later. This option
was also omitted due to various problems like storage, accessibility,
availability and volume of infusion. After the discovery of cryoprecipitate
in 1964, there was a change in the situation, Higher plasma levels could
be achieved without volume overload. After the discovery of lyophilized
clotting factor concentrates in 1958, prophylactic replacement with
clotting factors become possible.
The discovery that cryoprecipitate fraction of plasma was enriched
with FVIII and also the eventual discovery of purification of factor VIII
and factor IX from plasma, led to home infusion therapy in
1970s1.Further in 1990s both recombinant FVIII and FIX proteins were
given licence for infusion.
Prevalence
Hemophilia affects 1 in 10,000 males world wide. Among this
hemophilia A represents 80% of all cases. Male subjects are clinically
affected while women who carry single mutated gene ,are usually
asymptomatic. Around 30% of cases have no family history. Among
these 80% of women are carriers of de novo mutated allele.
Figure 2. PATTERN OF INHERITANCE IN HEMOPHILIA
Clinical features
Early in life the most common presentation is bleeding after
circumcision or very rarely as intracranial hemorrhages. During
childhood period, the disease is more commonly evident when child
begins to crawl or walk.
CLINICAL SEVERITY OF HEMOPHILIA:  (Figure 3)
CLINICAL CLASSIFICATION OF HEMOPHILIA : (Figure 4)
Clinical Classification of Hemophilia
Classification Severe Moderate Mild
Factor VIII or IX activity <1% 1% to 5% 6% to 30 %
Frequency of cases 50% to 70% 10% 30% to 40%
Causes of Bleeding Spontaneous Minor trauma,
rarely,spontaneous
Major Trauma,
surgery
Frequency of Bleeding 2 to 4 times/
month
4 to 6 times/ year Uncommon
Pattern of Bleeding Joint, Soft tissue
bleeding aftr
circumcision ,
neonatal ICH
Joint, Soft tissues, ±
Bleeding after
circumcision, ±
neonatal ICH
Joint, soft
tissues, ±
bleeding after
circumcision
Acute hemarthrosis of right knee joint in a 12 year old child :( Figure 5)
Recurrent hemarthrosis is the most common manifestation of severe
hemophilia. The joints mainly involved are knees, elbows, ankles,
shoulders and hips. In acute cases, the joints are swollen and painful, and
clinical signs are local warmth and redness .Irritability and restricted
movement of affected joints are usually seen in very young children.
JOINT BLEED – MOST COMMON JOINTS INVOLVED :
( HINGE JOINTS DUE TO MORE FRICTION) Figure 6:
Acute hemarthrosis of left knee joint in adult patient: (Figure 7)
In chronic hemarthrosis, synovial thickening and synovitis occurs.
Recurrent bleeding episodes into the same joint result in joint damage and
progressive joint deformity. Muscle hematomas may cause external
compression of neurovascular structures that can lead to compartment
syndrome.
Epistaxis, oropharyngeal or retropharyngeal bleeding are  the usual
presentation  of  mucous membrane bleeding. Gastro intestinal tract
bleeding occurs in a small percentage of patients. Bleeding into the
retroperitoneal space, with formation of masses with calcification and
inflammatory tissue reaction is known as pseudo tumor syndrome.
Left sided intra cerebral hemorrhage in a 12 year old child after
trauma: (Figure 8)
Major cause of death in patients with hemophilia is Central
nervous system hemorrhage2. Bleeding is usually post traumatic in
children; in adults the bleeding is usually spontaneous. Headache,
vomiting and seizures usually precede onset of CNS bleeding. Focal
neurological deficits occur depending on the site of bleeding.
Pseudo tumors are caused by recurrent hemorrhages in bone or soft
tissues. They can be found in muscle planes or sub periosteal region,
buttock, pelvis and thighs .Pseudo tumors can cause resorption of
neighboring bone or erosion of bony cortex. Usually asymptomatic unless
neuro-vascular compromise occurs.
Pseudo cyst involving right proximal femur :(Figure 9)
Hematuria can be seen in severe hemophilia. Trauma and exercise
may precipitate genitourinary bleeding. Antifibrinolytics and factor
replacement may cause acute hydronephrosis in patients with hemophilia.
Dental extraction can cause delayed bleeding, therefore patients require
prophylactic factor replacement before and after the procedure. If not
treated appropriately bleeding can persist and extend as sublingual,
pharyngeal and neck hematomas.
Sites of bleeding:
Serious - Joints
Muscle
Mucous Membranes in Mouth, Gums
Genitourinary Tract Bleeding
Life threatening - Intracranial Bleed
Chest
Neck
Throat
GI Tract
TREATMENT:
Severe hemophilia has a limited life expectancy if not treated
appropriately. Treatment for hemophilia involves a multidisciplinary
approach.(Figure 10).
TREATMENT PROTOCOLS :
ON DEMAND TREATMENT:
Replacement of deficient factor at the time of clinically evident bleeding.
Prophylaxis
Replacement of deficient factor to prevent bleeding.
Continuous prophylaxis:
FVIII 3days per week (or) FIX 2 days per week for 45 to 52 weeks per
year.
Continuous
Treatment
protocol
Prophylactic
Intermittent
On demand
Intermittent Prophylaxis:
Prophylaxis given for < 45 weeks per year
Treatment modalities available:
1. FVIII Concentrate:
 One unit is defined as amount of FVIII (100ng per ml) in 1 ml
of normal plasma.
 1 unit  per kg of FVIII concentrate – increase FVIII level by 2 %
 Half-life of FVIII is 8 to 12 hours.
 FVIII dose (IU) = Target FVIII level – FVIII baseline levels x
Body weight (kg) x 0.5 unit per kg.
 Given as a slow IV infusion over 3ml per min.
 Requires injection twice a day to maintain therapeutic levels.
 Fifteen minutes after the infusion factor level should be
measured to verify the calculated dose.
 Further doses based on the half-life of FVIII and patients
clinical improvement.
2. FIX concentrate:
 Treatment of choice for hemophilia B
 One unit is defined as amount of FIX (5ng per ml) in 1 ml of
normal plasma.
 1 unit per kg of FIX concentrates – increase FIX level by 1%.
 Half-life of FIX is 24 hours.
 FIX dose (IU) = Target FIX level – FIX baselinelevels x Body
weight (kg) x 1 unit per kg.
 Two classes of FIX concentrate available
1. Pure FIX concentrate
2. Prothrombin complex concentrate (PCCs):
It contain factors II, VII, IX and X.
 Pure FIX concentrates are preferred for treatment because
Prothrombin complex concentrates carries the risk of
thrombosis or disseminated intravascular coagulation (DIC).
 Each unit of FIX infused will increase the FIX level by
0.8IU/dl in adults and 0.7IU/dl in children.
 Given as slow IV injection at a rate of 3ml per minute in
adults and in children 100 units per minute.
SUGGESTED PLASMA FACTOR PEAK LEVEL AND
DURATION OF ADMINISTRATION (Figure .11)
Type of
Hemorrhage
HEMOPHILIA A HEMOPHILIA B
Desired
level
IU/dl
Duration (Days) Desired
Level
IU/dl
Duration
(Days)
Joint 40–60 1–2,may be longer if inadequate
response
40–60 1–2, may be
longer if
inadequate
response
Superficial
muscle/no
NV
compromise
(except
iliopsoas)
40–60 2–3, sometimes longer if response
is inadequate
40–60 2–3,
sometimes
longer if
response is
inadequate
Iliopsoas With NV compromise
Initial 80–100 1–2 60–80 1–2
Maintenance 30–60 3–5, sometimes longer as
secondary prophylaxis during
physiotherapy
30–60 3–5,
sometimes
longer as
secondary
prophylaxis
during
physiotherapy
CNS/head
Initial 80–100 1–7 60–80 1–7
Maintenance 50 8–21 30 8–21
Throat and neck
Initial 80–100 1–7 60–80 1–7
Maintenance 50 8–14 30 8–14
Gastrointestinal
Initial 80–100 7–14 60–80 7–14
Maintenance 50 30
Renal 50 3–5 40 3–5
Deep
laceration
50 5–7 40 5–7
Surgery (major)
Pre-op 80–100 60–80
Post-op
60–80
40–60
30–50
1–3
4–6
7–14
40–60
30–50
20–40
1–3
4–6
7–14
Surgery (minor)
Pre-
op
50–80 50–80
Post-op
30–80
1-5, depending on type of
procedure
30–80 1–5,
depending on
type of
procedure
SCHEMATIC DIAGRAM OF FVIII ACTIVITY :( Figure 12)
3. Cryoprecipitate
 Prepared by slow thawing of fresh frozen plasma (FFP) at 40
Celsius for 10-24 hours and it is separated by centrifugation.
 Rich in FVIII, vWF, Fibrinogen and FXIII but not  IX and XI.
 Cryo-poor plasma is a supernatant solution ,it contains factors
VII, IX, X and XI.
 Cryoprecipitate is used only when FVIII concentrates are not
available.
 It is still in use in developing countries.
 It carries the risk of transmitting blood borne diseases.
 One bag of cryoprecipitate prepared from one unit of fresh
frozen plasma (FFP) may contain 70-80 units of FVIII in a
volume of 30-40 ml.
4. Fresh frozen plasma (FFP):
 It contains all coagulation factors.
 Cryoprecipitate is preferable to FFP for treatment of hemophilia A.
 FFP and cryo-poor plasma can be used for treatment of hemophilia B,
as both products contain FIX.
 1ml of FFP contains 1 unit of factor activity
 Starting dose 15 to 20 ml per kg
 Difficult to achieve FVIII levels higher than 30 IU /dl and FIX
levels >25 IU/dl with FFP alone.
5. Non transfusion therapy in hemophilia:
Apart from conventional coagulation factor concentrates other
agents used in hemophilia are,
a .Desmopressin
b. Tranexamic acid
c. Epsilon aminocaproic acid
a. Desmopressin:
 Synthetic analogue of vasopressin also known as DDAVP ( 1-
deamino-8-arginine vasopressin )
 It causes transient increase in FVIII and  von will brand factor
(vWF ) by releasing from endothelial cells.
 Treatment of choice for mild or moderate hemophilia A.
 It is of no value in hemophilia B as it does not increase FIX
activity.
 Prior to therapeutic use each patient should be tested for its
response as there are significant difference between individuals.
 It is mainly used for treatment and prevention of bleeding in
hemophilia carriers.
 Advantages:
Lower cost
No risk of transmission of blood born infections.
 Dosage and administration:
Preparations available:
1.4 µ g/ml for IV use
15 µ g/ml for IV and SC use
150 µ g per metered dose as nasal spray
0.3 µ g /kg body weight as single dose can increase the factor
level by three to six fold.
 In intravenous and subcutaneous form the peak response usually
seen after 60 minutes.
 Repeated uses over several days causetachyphylaxis.
 Side effects:
 Tachycardia, fiushing, abdominal discomfort and
tremor occurs if it is given as a rapid intravenous
infusion.
 Water retention and cerebral edema
 Hypernatremia
 Risk of thrombosis
 Contraindicated in patients with seizures and
cardiovascular disease.
b.Tranexamic acid
 It is an antifibrinolytic agent.
 Competitively inhibits the activation of plasminogen to plasmin.
 It is mainly used as adjunctive therapy in hemophilia as it promotes
clot stability.
 Indications:
 Epistaxis
 Oral mucosal bleeding
 Menorrhagia
 Prior to dental extraction
 No role in prevention of hemarthrosis if it is used alone.
 Dosage and administration
Preparations available:
Oral - 25mg/kg 3 to 4 times a day for one week or longer.
o Slow intra venous injection
o Mouthwash for pediatric use
 Contraindications:
 Hematuria – causes obstructive uropathy
 During thoracic surgery – forms insoluble hematoma
 When it is used along with Prothrombin Complex
Concentrates (PCCs) in patients with hemophilia, this
will exacerbate the risk of thromboembolism.
Epsilon aminocaproic acid (EACA):
 It is similar to tranexamicacid.
 Because of shorter plasma half-life and less potency it is rarely
used.
 Dose : Requires loading dose of 200mg/kg followed by
100mg/kg/dose every sixth  hourly.
 At high therapeutic doses it inhibits the activity of factor VIII
inhibitor4.
 Side effects:
Gastrointestinal upset
Myopathy – reversible after stopping the drug.
GENE THERAPY IN HEMOPHILIA:
Gene therapy for hemophilia is under research. Viral and non-viral
vectors containing factor VIII or IX gene has been used for this purpose.
Success of gene therapy has been demonstrated in animal models but not
in humans. Inflammatory response, oncogenesis, inhibitor development
and germ line mutations are the risks associated with gene therapy.
GENE THERAPY FOR HEMOPHILIA :(Figure 13)
COMPLICATIONS:
MUSCULOSKELETAL:
ACUTE COMPLICATIONS:
 Muscle hematoma
 Hemarthrosis
 Acute synovitis
ACUTE SYNOVITIS:
Inflammation of synovium secondary to acute hemarthrosis causes acute
synovitis. The synovium becomes inflamed, hyperemic and extremely
friable. If appropriate treatment is not initiated at this stage it can result in
repeated hemarthroses. In early stages movement of the joint is preserved
MUSCULOSKELETAL
ACUTE
COMPLICATIONS
CHRONIC
TRANSFUSION
RELATED
ACUTE CHRONIC
and differentiation from  acute hemarthrosis is made by complete
examination of the joint.
DIAGNOSIS:
Acute synovitis is diagnosed by ultrasonography or MRI.
Ultrasonography reveals the presence of synovial hypertrophy and the
extent of osteochondral damage is detected by plain xray or MRI.
TREATMENT:
 Preservation of joint function is the primary goal of treatment.
 Replacement of factor concentrates as early as possible can prevent
the recurrent bleeding.
 Short term secondary prophylaxis for one month is advised if
factor concentrates are available.
 Physiotherapy to improve the muscle strength.
 COX-2 inhibitors can be used for reducing the inflammation.
CHRONIC COMPLICATIONS:
 Chronic synovitis
 Chronic hemophilic arthropathy
 Pseudo tumours
 Fractures
CHRONIC SYNOVITIS:
If acute synovitis is not treated properly, it can result in repeated
hemarthroses and the synovium becomes chronically inflamed and
hypertrophied. It can result in atrophy of muscles, articular damage,
limitation of joint movements and progress to chronic hemophilic
arthropathy.
TREATMENT:
If chronic synovitis is not responding to conservative management
synovectomy should be considered. Options available
 Chemical synovectomy
 Radioisotopic synovectomy
 Surgical synovectomy ( open or arthroscopic )
CHRONIC HEMOPHILIC ARTHROPATHY:
Chronic hemophilic arthropathy is a terminal stage of
hemarthrosis. It can develop early in life in patients with severe
hemophilia.
It is characterized by,
 Fibrous and bony ankylosis of major joints.
 Secondary soft tissue contractures
 Atrophy of muscles
 Angular deformities
 Flexion contractures
 Painful joint movements
PATHOGENESIS:
DIAGNOSIS:
Early arthropathy can be best diagnosed by magnetic resonance
imaging of the joint. A scoring system has also been reported for chronic
hemophiliac arthropathy by using MRI.
Radiograph depicting advanced hemophilic arthropathy of the knee
joint. showing chronic severe arthritis, large synovial cyst, fusion and
loss of cartilage.(Figure 14).
MRI PICTURE SHOWING CHRONIC HEMOPHILIC
ARTHROPATHY OF KNEE JOINT :(Figure 15)
Scoring system for hemophiliac arthropathy by using MRI :( Figure 16)
Score Abnormalities on imaging
0 None
I Minimal hemosiderin
II Large amount of hemosiderin and cartilaginous erosion
III Cartilage destruction, bone erosion and sub chondral cysts
IV Osteoarthritis with or without ankylosis
Chronic hemophilic arthropathy of knee joint:(Figure 17)
TREATMENT:
 COX-2 inhibitors can be used for relieving arthritic pain.
 Supervised physiotherapy to improve the muscle strength.
 Conservative management like serial casting, bracing and orthotics.
 Surgical management like extra-articular soft tissue release,
arthroscopy, osteotomy, synovectomy and prosthetic joint
replacement if conservative treatment fails.
FRACTURES:
Fractures are common in bones around the joints because of
significant osteoporosis and lack of movements. Urgent factor
concentrate replacement is the treatment of choice. Factor concentrate
should be given for three to five days to maintain the factor levels above
50%.
INHIBITORS:
Major complication of hemophilia is development of inhibitors to
FVIII and FIX. These are alloantibodies( IgG ) to FVIII or FIX.
Prevalence rate is more common in hemophilia A than in patients with
hemophilia B. Patients with severe disease more likely to have inhibitors
than in those with mild disease.
RISK FACTORS FOR DEVELOPMENT OF INHIBITOR:
HIGH RISK GROUPS:
 Patients with hemophilia A
 Patients with severe disease
 Family history of inhibitor
 Mutations in the FVIII or FIX gene
 Intensive factor replacement
 African descendants
The presence of inhibitors should be suspected if the patient is not
responding to factor concentrates.
INCIDENCE:
In severe hemophilia A approximately 25% of patients have FVIII
inhibitors9,11. In patients with mild and moderate disease only 3 to 13% of
patients having the risk of developing inhibitors10, 11, 12.
HEMOPHILIA FACTS IN INDIA :(Figure 18)
In severe hemophilia B approximately 3 to 5% of patients having
the risk of developing inhibitors to FIX.
During routine screening approximately 50% of the patients with
inhibitors, the titer were or become low or disappear in spite of continued
factor concentrate exposure. These transient inhibitors are more common
in patients with low inhibitor titers.
In a trial there was 36% risk of developing inhibitors in those with
severe disease after 18 days of exposure. Another trial done with
recombinant FVIII had similar results with 38% having the risk after 25
days of exposure13. where as lower risk of developing inhibitor was there
in previously treated patients but this result may be due to selection bias
because generally development of inhibitors occurs early so the group of
previously treated patients  may represent a lower risk group14,15.
A study was done in UK between 1992-2009 in patients with
severe hemophilia to analyze the age adjusted incidence of new FVIII
inhibitors  total of 2528 patients were followed up for twelve years and
about 315 new inhibitors were reported. The two points of interest from
these results were
1. There was bimodal risk in development of FVIII inhibitor one is in
early childhood and another in old age. The reason for risk in old
age is poorly understood may be due to decrease in immune
tolerance with increasing age.
2. There is need of close monitoring in older patients with FVIII
deficiency for development of inhibitors, it may be useful if they
need surgery or treatment with antithrombotic for age related
disease.
Predisposing factors:
Inhibitor formation is influenced by the both host and product
factors.
Host related factors:
Patients with large deletions and stop mutations having high
likelihood for inhibitor formation compared to patients with small
deletions or missense mutaions16-18.Patients with gene inversions having
moderate risk for inhibitor formation19. International electronic database
shows the relationship between FVIII mutation type and inhibitor
development20,21:
 Large deletions - 38 %
 Nonsense mutations - 36 %
 Inversions - 20 %
 Small deletions - 14 %
 Missense mutations - 7 %
 Insertions - 7 %
 Splice site mutations - 4 %
In UK one third of hemophilia A population with nonsense mutations
involving 3’ end of FVIII gene having higher risk for inhibitor
formation22.
In patients with severe disease the complete absence of FVIII
prevents the fetal induction of tolerance and predisposes them to inhibitor
formation after exposure to normal factor VIII concentrates. This same
concept responsible for the lower frequency of inhibitor formation in
patients with mild and moderate hemophilia10, 11, 13. Among these patients
the antibodies are not directed against the self-factorVIII, only against
wild type factor VIII12,23.
Patients with family history of inhibitors having high chance of
inhibitor formation, this is evidenced in a study that showed siblings of
patients with hemophilia and factor VIII inhibitors have an increasedrisk
of inhibitor formation11,17,24,25.C2 domain or A2 domain mutations,
especially during perioperative period and cumulative factor exposure,
may predispose to inhibitor formation26,27. The role of HLA class II
antigens has also been described. Interleukin-10 and cytotoxic T-
lymphocyte associated protein -4 gene polymorphisms also been
associated with antibody development27-29. Studies also show the
relationship between polymorphism in the tumor necrosis factor alpha
gene and risk of inhibitor development in patients with severe hemophilia
A27, 30.
Product related factors:
Inhibitor formation occurs with certain preparations of factor
concentrate products31,32.This is suspected when inhibitor formation
occurs in a frequently transfused patients who have been transfused with
new product. Recombinant products might cause higher antibody
formation than plasma derived products has not been proven33, 36.
Inhibitor formation may be influenced by patient’s age at various
stages like at the time of initial transfusion, intensity of treatment and
early use of prophylaxis.
 A study  done about importance of age on incidence of FVIII
inhibitors in severe hemophilia revealed that the incidence was
about 41,29 and 12 percent for those starting initial infusion at less
than six months, six to twelve months and more than twelve
months respectively37,38.
 In CANAL study done in 366 patients with severe hemophilia who
were previously untreated, the development of inhibitor with
clinical relevance seems to be associated with first treatment at
earlier age but there was no association when adjustment for
treatment intensity was made18. Also there was increased risk of
inhibitor formation in patients with family history. The study also
revealed the incidence of inhibitor formation was more in patient
treated for surgical procedures first when compared to patients
treated for bleeding or prophylaxis. In same study patient who had
regular prophylaxis was at sixty percent lower risk than patient
with on demand treatment.
 Study done by Rivard et al revealed that there was no influence on
development of inhibitor by delaying FVIII exposure during first
two years of life, only delay its onset39.
 Another study done revealed that there was no influence on
inhibitor development in relation with age at which first FVIII
infusion was done17.
 A case control study done with 36 cases with mild or moderate
hemophilia A and inhibitor and 62 controls without inhibitors
among these treatment with FVIII for six or more consecutive days
during previous one year was associated with inhibitor
development in those with more than 30 years of age. Among 14 of
17 subjects with >30 years of age the common indication for FVIII
treatment was surgery, among these 79% were orthopedic40.
It is not clear whether these findings are reflections of plasma
factor VIII antigen concentration or differences in type of mutation.
Race and FVIII polymorphisms:
Another important factor in inhibitor development is race .The
MIBS study revealed that the incidence of inhibitor formation is more in
black subjects when compared to Caucasians which is around 56% and
27% respectively41.
 In a study done on 86 white subjects for six FVIII haplotype
containing single nucleotide polymorphisms (SNPs), H1 and H2
were the only prevalent types 42.
 H3, H4, H5 were prevalent only in sixteen black subjects. H6 was
found only among ten Chinese subjects.
 The current FVIII products approved for hemophilia A corresponds
to haplotype 1 and 2 respectively.
The reason for increased incidence of inhibitors among black
patients is because 1 in 4 patients with hemophilia A will receive
replacement products that differ from their own factor at one or two
residues42.
For a patient hemophilia with null mutation the presence are lack
of haplotype in infused factor should not matter because the patient do
not have circulating factor VIII in vitro. This possibility of null mutation
explains discord between Caucasians and non-Caucasians.
To explain this discord with less than one percent factor VIII activity a
bigger heterogeneous cohorts of hemophilia A and it also requires
sophisticated immunological testing.
RISK SCORE:
A risk score was developed based on CANAL study for development
of FVIII inhibitors43 .It included
1. Family history of development of inhibitors – 2 points
2. Presence of high risk gene mutation - 2 points
3. Intensive treatment of first episode - 3 points
A cohort study done in 332 patients showed those with risk score
of 0,2 and more than 3 were 6,was 23 and 57 percent respectively.
Similar incidence was also seen in another study of 64 patients.
CLINICAL MANIFESTATION OF FVIII ANTIBODIES:
It depends upon the severity of disease. Normally the inhibitor
development does not lead to increase in frequency of bleeding events
except in some conditions like a moderate deficient patient is converted
into severe state due to inhibitor development. These patients will have
more difficulty in achieving hemostasis and also they have more
musculoskeletal complications44.
Presence of these inhibitors may make treatment of bleeding
episodes much difficult hence if a patient with severe hemophilia in
whom there is refractory bleeding episode to usual therapy we should
suspect an inhibitor.
In patients with mild to moderate disease the presence of inhibitor
may induce the bleeding episodes and they convert the patient to a more
severe phenotype.
A study done in 26 patients with mild to moderate hemophilia for
the development of inhibitors, most of these patients developed inhibitors
only after receiving intensive factor replacement therapy11. Among them
22 patients had spontaneous bleeding. Among these eight patients had
persistent inhibitors for more than eight years and in the remaining
patients the inhibitors disappeared after a period of nine months.
STRUCTURE OF FVIII :( Figure 19)
Structure of factor VIII consists of a heavy chain, connecting region and
light chain. Heavy chain consists of A1 and A2 domains, connecting
region with   B1 domain and a light chain with A3, C1, and C2 domains.
FVIII inhibitors are formed against certain specific epitopes of FVIII
molecule, commonly against the C245, 46, A2 45, 47, 48 and light chain
domains like A345, 49. A study was conducted in 36 patients with
hemophilia A, among them in eighty two percent of the patients the
antibodies were directed against the C2 domain, in seventy percent of the
patients A2 domain and both in twenty five percent of the patients. But in
acquired hemophilia the patients usually have antibody directed against
C245.
MECHANISM OF ACTION:
 Normally the C2 domain binds to the phospholipids on activated
platelets, endothelial cells and to the vWF. Antibodies against C2
domain causes loss of procoagulant activity and rapid degradation
of von willebrand factor (vWF).
 Antibodies against A2 domain blocks the conversion of factor X to
Xa.
 Antibodies against A3 domain interfere with the generation of
factor Xa45,49.
 A study was conducted in twenty four patients with severe
hemophilia and FVIII inhibitors, among significant proteolytic
activity was detected in thirteen patients.
DIAGNOSIS OF INHIBITOR:
Bethesda assay is used for the measurement of factor VIII
inhibitor, which also gives the quantity of antibody titer.Annual screening
of inhibitor is essential for early diagnosis and eradication of the
inhibitor.
BETHESDA ASSAY:
In this assay serial dilutions of test plasma is incubated with pooled
normal plasma for the period of two hours at 370C ,then by using clotting
assay the residual factor VIII level is measured. The results are expressed
in Bethesda units.1 Bethesda unit( BU) is defined as amount of antibody
that neutralizes 50% of the factor VIII or factor IX present in normal
plasma after two hours of incubation at 370C51. Greater dilution is
required in patients with high antibody titers to measure the residual
factor VIII activity. Depending on the pattern of response the inhibitor
patients are classified as high responders or low responders.
HIGH RESPONDERS:
Patients with antibody titer of more than five Bethesda units (BU)
is defined as high responders6 .The development of inhibitor is
immediately after the exposure usually starts within two to three days,
peaks at 7 to 21 days. After each exposure the antibody titer will increase
and may persist for years in the absence of re-exposure 7, 8. These patients
are not responding to factor VIII concentrates and require bypassing
agents5.
LOW RESPONDERS:
Patients with persistent low inhibitor titer(< 5 BU) that may
disappear and do not increase after re-exposure. These patients are
usually responds to factor VIII or factor IX transfusion in high doses5.
For patients with low titer inhibitors the Nijmegen modification of
Bethesda assay has improved specificity and reliability52. Quantitative
measurement of factor VIII antibodies can be done by using
immunoassay53.
TREATMENT:
Treatment consists of two components
1. Treatment of active bleeding episodes
2 .Eradication of inhibitor
TREATMENT OF ACTIVE BLEEDING:
Treatment for active bleeding depends on the inhibitor type (High
versus Low responders)
TREATMENT OF ACTIVE BLEEDING IN HIGH RESPONDERS:
There are many treatment centers for hemophilia which provides
expertise treatment for these specialized patients and these centers should
be consulted before developing a new mode of treatment for patients with
inhibitor. By advancing treatment methods there is improvement in final
outcome and prognosis. A study done among patients from Finland the
annual mortality rate reduced from 42 to 5 .8 per thousand patients 11.
There are some guidelines available like United Kingdom hemophilia
center doctors organization guidelines. Though quality of life improves
treatment is expensive.
In the high responder group if the patient is having bleeding in the
usual sites, inhibitor bypassing agents should be used irrespective of the
present inhibitor titer. Bypassing agents commonly used are,
1. Prothrombin Complex Concentrates (PCCs) and their activated
counterparts (aPCCs)
2. Recombinant Factor VIIa(rFVIIa)
3. Porcine Factor VIII
1. Activated Prothrombin Complex Concentrates (aPCCs):
Activated Prothrombin Complex Concentrates are prepared by
increasing the concentration of active proteases to the Prothrombin
Complex Concentrates (PCCs).The only aPCC available in market for use
is FEIBA® (Factor eight inhibitor bypassing activity ).Previously used
preparation the Autoplex® has been removed from the market58-60.A
study was conducted in France in sixty patients with inhibitors who were
treated with FEIBA ,among them eighty one percent had
goodclinicalimprovement, seventeen percent had poor outcome and
nonexistent in 2%.
TREATMENT STRATEGIES FOR PATIENTS WITH
HEMOPHILIA WHO DEVELOP INHIBITORS:
FACTOR CONCENTRATES USED IN PATIENTS WITH HIGH
TITER INHIBITORS : (Figure 20 )
Factor concentrate Advantages Disadvantages
1.Porcine (p) FVIII
FVIII levels can be
measured.
Inhibitors often cross
react with pFVIII.
Risk of transmission of
porcine viruses.
2.Prothrombin
complex concentrates
(PCCs )
Bypass the need for
FVIII.
Relatively cheap.
Inferior to aPCC in
terms of efficacy.
Risk of thrombosis and
infusion associated
side effects.
3.Activated
prothrombin complex
concentrates (aPCCs)
80-90% clinical
efficacy.
Cost effective than
rFVIIa.
Long half-life than
rFVIIa.
More effective than
Hemostatic response is
unpredictable.
Risk of thrombosis and
transmission of human
viruses.
No effective laboratory
parameter to monitor
PCCs. efficacy and optimal
dosing.
Anamnestic response.
4.Recombinant factor
VIIa (rFVIIa)
80-90% clinical
efficacy.
No risk of
transmission of
viruses.
No anamnestic
response.
Hemostatic response is
unpredictable.
Risk of thrombosis.
No effective laboratory
parameter to monitor
efficacy and optimal
dosing.
Short plasma half-life
than aPCCs.
Dose of aPCCs is 50-100 IU /kg every 8 to 12 hours up to three
doses, daily doses more than 200 IU / kg should be avoided because of
risk of disseminated intravascular coagulation (DIC).
The compound responsible for hemostasis in aPCCs is activated
protease which has short half-life, so there may be risk of breakthrough
bleeding in between the doses. The major risk of PCCs and aPCCs is
thrombosis, both may cause thrombosis in coronary arteries especially if
large doses are given54, 61.
Another disadvantage of using PCCs and aPCCs is there is no
reliable laboratory parameter available to monitor the hemostatic efficacy
of these products. The efficacies of these products vary between
individuals and with type of hemorrhage. So for treating hemophilia
patients with inhibitors certain general guidelines may be used designed
by the experienced hematologist5.
To summarize treatment with PCCs or aPCCs is costly, hemostatic
response is unpredictable with no reliable laboratory parameter to
monitor the response and it is thrombogenic.
A small study was done in hemophilia patients with inhibitors, it show
the role of thrombin generation tests (TGT) to assess the effectiveness of
PCCs and aPCCs62.
2. PORCINE FVIIICONCENTRATES:
Porcine factor VIII is prepared from the plasma of pigs. It is
usually indicated in high responders with life threatening bleeding55-57.
The disadvantage is inhibitors viruses. But as of now plasma derived
porcine factor VIII is unavailable in market.
3. RECOMBITANT FACTOR VIIa (rFVIIa):
Majority of the patients respond effectively to recombinant human
factor VIIa, the advantage mainly being lack of systemic coagulation as
seen with others because of its act locally63-69. Available products Novo-
Seven®,rFVIIa.
 Initial dose: 90-120 µg/kg every 2 to 3 hours till hemostasis is
established. Dose and duration of interval depending upon the
individual clinical scenario. Based on a case with symptoms of
severe joint, muscle and mucocutaneous bleeding an average of 2.2
doses was needed to achieve hemostasis64.
 In case of patients requiring surgery an initial dose of 90-120µg/kg
is used. Another trial suggests 90µg /kg dose is superior to 35µg
/kg65. Two of the following studies describe the method of
administration of rFVIIa
 28 patients having factor VIII inhibitors was treated with initial
dose of 90-150µg/kg given as bolus dose for ten hemorrhagic
events, eleven and fourteen major and minor surgical procedures
respectively following which continuous infusion of 16µg/kg/hr.for
spontaneous bleeding, 17µg/kg /hr for minor and 20µg/kg /hr. for
major surgery was given.86 % among them showed perfect
hemostasis 68.
 Nine patients with FVIII inhibitors planned for major orthopedic
surgery was treated with recombinant factor VIIa(rFVIIa) as bolus
infusion of 90µg/kg  just before the procedure followed by
continuous dose of 50µg/kg  /hr over a period of twenty days with
target VIIc levels more than 30 IU/ml69.Six among the above
showed hemorrhagic events postoperatively who were treated with
60µg /kg  /hr as a bolus and overall outcome is satisfactory in all
the case.
Based on above  studies achieving factor VII c level of 30 t0 40
IU/ml post operatively provides sufficient safety margin in  most of the
cases when compared to 10 IU/ml in a steady state.
Another study done in twenty four patients undergoing surgery for
continuous infusion dosing with bolus, the results suggested that after ten
days of treatment the hemostatic efficacy and safety between continuous
infusion and bolus were judged to be comparable71.
Regarding high dose regimen there were three studies done to
evaluatethe advantage of high dose over standard dose in efficacy, safety
and to control bleeding in home treatment setting 72-75.
Among these three studies one study was done to compare current
standard therapy to single dose therapy ,both were equally effective in
controlling bleeding and the amount of drug used was similar. Same
results were seen in other studies too.
So as per these studies high dose regimen seems
 Safe.
 Requires minimal number of dose.
 Effective.
 Does not increase recombinant factor VIIa consumption.
 Convenient in difficult venous access patients.
 For rapid control of bleeding.
Hence the high dose of 270µg /kg was approved by European
medicines agency 75.
Prophylactic use:
A study was done in 22 patients with high baseline bleeding
frequency were allotted randomly for daily prophylaxis of recombinant
factor three months76. The results were there was reduced bleeding
frequency during prophylaxis and it was maintained during post
prophylactic period.
Though there was reduced incidence in all types of bleeding it was
more in spontaneous joint bleeds. There were no thromboembolic events
during prophylactic therapy. Also further analysis of quality of life was
done in these patients and there was significant improvement during
treatment and after prophylaxis77.
A study done by comparing recombinant factor VIIa with activated
PCCs also known as FENOC study it is an open label randomized
prospective cross over study. The study was planned to evaluate
equivalence between aPCCs and rFVIIa.
 48 patients were analyzed.
 Data of 96 episodes of bleeding were collected and evaluated.
 The efficacy rate was 80-90% for both.
 Exploratory analysis was done neither product was superior to
other in terms of ability to stop bleeding or efficacy.
When these two drugs are used together, several studies have
proved there is increased risk of thrombosis. A study done in 49 patients
revealed that concurrent use of these two agents resulted in thrombotic
events ,hence based on these studies even the hemostatic efficacy was
better due to thrombotic episodes these dual drug treatment parallelly
should be reserved for severe bleeding episodes when there is no other
treatment option78-80.
Activated Prothrombin Complex Concentrates (aPCCs) when
infused rapidly causes activation of bradykinin and complement system
which causes hypersensitivity reactions, also rapid infusion causes other
complications like myocardial infarction, disseminated intravascular
coagulation (DIC) .54
Recombinant factor does not cause such antibody response; also
there is decreased incidence of DIC and thrombosis. This difference is
due to more localized hemostatic control.
Perioperative management in high responders:
There should be great caution while a patient with high responding
inhibitors is taken for surgery. Successful protocol should be selected for
such perioperative management. The options include5
 Recombinant factor VII a in bolus dose of 90 to 120µg/kg every
two hours for first 48 hours.
 FEIBA in a dose of 200 units per kilogram per day for first 2 to
4 days for major surgery and for minor surgery 150 units/kg/day
for three days.
TREATMENT OF ACTIVE BLEEDING IN LOW RESPONDERS:
1. High purity factor VIII concentrates :
 Can be used in patients with inhibitor levels less than ten Bethesda
units.
 Main use is in patients whose inhibitor level are reduced by
plasmapheresis or immunoadsorbtion with emergency surgery or
severe hemorrhage8.
 Although there is no proper validation for dosing of factor VIII in
presence of inhibitor the following method can be used
Initial loading dose = weight (kg) x 80 x antibody titer x (1-
hematocrit)
along with additional 50 IU/kg body weight.
After fifteen minutes of continuation of bolus FVIII levels should
be checked and dose should be analyzed accordingly.
ERADICATION OF INHIBITOR BY ITI:
Immune tolerance induction (ITI) the method by which patients
immune system is reset by regular administration of deficient factor.
There are many protocols with different dosing regimens or protocols
with or without immunosuppressive therapy or use of bypassing agents.
A prospective study done by comparing high dose with three times
weekly low dose had ITI as its primary end point but the study was
terminated early because of increased frequency of bleeding events81.
Factors affecting success of ITI:
 If antibody titer is less than ten.
 Younger patient.
 Lesser time interval between onset of inhibitor to ITI.
Before initiating ITI it is must to start at a low initial titer, so the
time taken to reach the low initial titer should be balanced. This time
allows inhibitors to become memory responses .If we take a decision to
wait for starting ITI until the titer reaches less than ten Bethesda units
(BU), the titer should be regularly followed to identify any changes in the
titer.
The main aim in long term management in patients with factor VIII
inhibitors is to eliminate the inhibitors82. The primary management
modality in ITI is via repeated administration of factor VIII with or
without immunosuppressive therapy. During this therapy there will be
anamnestic response causing rise in antibody titers which later
progressively get reduced to low or undetectable levels 8, 83. To maintain
immune tolerance there should be continuous exposure to factor VIII8.
There are many studies which deals with how desensitization
occurs on such study revealed that there is no change in concentration of
antibodies and the ability of antibody to inhibit the procoagulant function
of factor VIII84, 85. There was reduction in Bethesda assay level to
undetectable range; this was mainly due to anti idiotypic production of
antibodies. This antibody neutralizes inhibitory capacity of factor VIII
antibodies. Another study revealed that there was difference in original
inhibitor compared to circulating antibodies against factor VIII, they
differed in specificity there was no coagulation inhibitory activity, and
also these antibodies did not increase the elimination of factor VIII86.
SPECIFIC REGIMENS:
There was several types of regimen used and many studies was
done on these regimens, the results of these studies can be understood by
following data’s
 In a study done in twelve patients with factor VIII at a dose of
50unit/kg/day without adjuvant immunosuppressive therapy83.
After ten months of treatment the inhibitor levels become
undetectable in nine patients, so these nine patients require smaller
or less frequent infusions. Whereas the remaining three non-
responders had higher inhibitor levels.
 Another multicenter study was done in 158 patient’s .Among these
158 patients 39 patients did not respond 87, 12 patients had partial
tolerance, and rest of the patients had complete tolerance. This
study further revealed that patients with low level of inhibitors and
who was given higher doses had successful results even though
many patients were high responders. This tolerance was long
lasting and only one among patients with complete tolerance had
relapse.
 A study done using questionnaire on data of 188 courses of ITI
.This data was received from North American immune tolerance
registry89. Based on these data the success of immune tolerance
therapy (ITT) was dependent on peak inhibitor titers before and
during ITT.
 Another study was done in Italy also known as PROFIT study
 Done as a part of Italian ITI registry
 86 patients were recruited
 Study was done to know relationship between factor VIII mutation
and inhibitor formation.
 81 percent of patients had factor VIII mutations with high risk for
inhibitor formation.
 The rest 19 percent had low risk mutation
 Among high risk mutation there was large deletions, inversions,
nonsense mutations, splice site mutations.
 Among low risk mutations there was small insertions, deletions,
non sense mutations
 Although there was no uniformity in manner of performing ITI or
uniform time after development of inhibitor the following
observations were made, the ITI success rate was more in low risk
mutation group than that of high risk mutation group which is 81
percent vs. 41 percent.
 Multivariate analysis was made on predictors of successful ITI and
those were 91
1. Mutation risk class.
2. Inhibitor titer less than 5 BU while starting ITI.
3. Peak titer less than 100 BU during ITI.
RITUXIMAB:
A chimeric monoclonal antibody against CD-20 .It is mostly used
in lymphomas, leukemias and auto immune disorders. Studies have been
done on effectiveness of rituximab in developing antibody to replacement
factor. In patients with high titer inhibitors rituximab has been tried with
some degree of success92-95.
TRANSFUSION RELATED COMPLICATIONS:
ACUTE COMPLICATIONS:
 Allergic reactions to factor concentrates may occur like fever,
headache and skin reactions.
 Rarely anaphylactic reactions occur.
 Transfusion related acute lung injury (TRALI) occurs especially
to blood products like whole blood, RBCs and fresh frozen
plasma (FFP).
CHRONIC COMPLICATIONS:
Before 1980s the most common cause of death in hemophilia is
HIV infection but after 1985 the risk of acquiring HIV infection is very
rare because of using newer methods for preparing FVIII concentrates
and the availability of serological tests for donor examination.
Transfusion related complications usually occur with older products.
 Hepatitis due to hepatotoxic viruses like hepatitis viruses A-E,
Epstein Barr virus and cytomegalovirus. Around 10% of patients
with HBV and HCV infection will go for chronic carrier state and
its complications like cirrhosis, hepatocellular carcinoma.
 Other viruses like human herpes virus 8 and parvovirus B19
infections can occur. Parvovirus infection can cause bone marrow
suppression, acute CNS infections and SLE like syndromes.
 Possible transmission of prion diseases like CJD or vCJD should
be monitored. As of now no patient is known to develop CJD96.
 Approximately 30-90 percent of patients treated with older less
pure factor concentrate developed HIV seroconversion and
progression to AIDS. For unknown reasons AIDS patients with
hemophilia do not develop Kaposi sarcoma3.
 Increased risk of bleeding in patients with hemophilia who use
protease inhibitors. Bone marrow suppression occurs secondary to
liver disease, viruses or as a side effect of HAART therapy.
 Immunosuppression occurs in patients who use intermediate purity
factor products. Transfusion of factor VIII to patients with
inhibitors can cause an anamnestic increase in inhibitor titers.
 Long term factor replacement for immune tolerance induction can
cause nephrotic syndrome.
MATERIALS AND METHODS
Study design: Observational study
Patient selection:
50 patients admitted in Coimbatore Medical College hospital with
severe hemophilia during the year August 2013 - July 2014.
Inclusion criteria:
 Patients admitted with severe hemophilia based on factor level.
 Hemophilia patients willing to participate in this study.
Exclusion criteria:
 Drug intake (penicillin, phenytoin, interferon).
 Known case of systemic lupus erythematosis, Rheumatoid arthritis.
 Patients with acquired hemophilia.
 Hemophilia patients not willing to participate in this study.
Techniques:
History and Examination:
All patients with hemophilia willing to participate in the study
were assessed as per the criteria submitted to institutional ethics
committee. Patients with severe hemophilia were taken based on factor
level from the patient records. Thorough history was taken about the
number of exposure to factor concentrates and blood products. Family
history was obtained in detail.
The factor levels are measured by Bethesda assay. Bleeding score
was based on the score set by the World Federation of Hemophilia.
Bleeding score was used to assess severity of the disease. Informed
consent was obtained from all patients before starting the study.
STATISTICAL METHODS:
Statistical analysis was performed using SPSS version 19.0 .Normal
data were measured using mean and standard deviation To correlate
various clinical variables Pearson correlation co-efficient with single tail
analysis was done.
RESULTS
Table 1. Type of hemophilia among the participants
Total number of
patients
Hemophilia A Hemophilia B
50 36 14
Chart 1. Type of hemophilia among the participants
Among the patients studied 72 percent had hemophilia A and the
remaining 28 percent had hemophilia B.
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Table 2. Age Distribution of severe hemophilia A
Age No. of patients
<10 3
10-19 15
20-29 9
30-39 5
40-49 2
50-59 1
>60 1
Chart 2 .Age wise distribution of severe hemophilia A
Among the patients the age ranged from 7 years to 64 years while most
were in second and third decades.
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Table 3. Age distribution of severe hemophilia B
Age No. of patients
<10 4
10-19 4
20-29 1
30-39 4
40-49 1
Chart 3 . Age wise distribution of severe hemophilia B
Among the patients the age ranged from 9 years to 48 years while
most were in first and second decades.
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Table 4. Age at the time of diagnosis of severe hemophilia A
Age (months)
<6 5
7-12 12
13-18 10
19-24 7
>24 2
Chart 4 . Age at the time of diagnosis of (months) severe hemophilia A
Among the patients studied, the age at the time of diagnosis were
ranged from less than 6 months to more than 24 months while most were
in 7 months to 18 months.
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Table 5. Age at the time of diagnosis of severe hemophilia B
Age (months)
<6 1
7-12 3
13-18 1
19-24 2
>24 7
Chart 5. Age at the time of diagnosis of (months) severe hemophilia B
Among the patients studied, the age at the time of diagnosis were
ranged from less than 6 months to more than 24 months while most were
in more than 24 months.
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Table 6. Number of cumulative exposure days to FVIII in severe
hemophilia A
Exposure days to Factor VIII No. of patients
<20 12
20-30 10
>30 14
Chart 6 .Number of cumulative exposure days to FVIII in severe
hemophilia A
Among the patients ,the number of  cumulative exposure days to
FVIII were ranged from <20 to >30 days while majority were received
factor for more than 30 cumulative exposure days.
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Table 7. Number of cumulative exposure days to FIX in severe
hemophilia B
Exposure  days to Factor VIII No. of patients
<20 9
20-30 2
>30 3
Chart 7. Number of cumulative exposure days to FIX in severe
hemophilia B
Among the patients, the number of cumulative exposure days to
FIX was ranged from <20 to >30 while most were received factor for less
than 20 cumulative exposure days.
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Table 8. Number of exposure to cryoprecipitate in severe hemophilia A
Exposure No. of patients
<10 11
10-19 9
>20 6
Chart 8. Number of exposure to cryoprecipitate in severe
hemophilia A
Among patients with hemophilia A, the number of exposure to
cryoprecipitate were ranged from < 10 to > 20 while most were exposed
to less than ten times.
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Table 9. Number of exposure to cryoprecipitate in severe hemophilia B
Exposure No. of patients
<10 5
10-19 8
>20 1
Chart 9 . Number of exposure to cryoprecipitate in severe
hemophilia B
Among patients with hemophilia B, the number of exposure to
cryoprecipitate were ranged from < 10 to > 20 while most were exposed
to 10-19 times.
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Table 10. Number of exposure to FFP in severe hemophilia A
Exposure No. of patients
<10 0
10-19 9
20-29 15
30-39 10
>40 2
Chart 10 . Number of exposure to FFP in severe hemophilia A
Among patients with hemophilia A ,the number of exposure to FFP
were ranged from < 10 to > 40 while most were exposed to 20-29 times.
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Table 11 .Number of exposure to FFP in severe hemophilia B
Exposure No. of patients
<10 0
10-19 4
20-29 4
30-39 5
>40 1
Chart 11. Number of exposure to FFP in severe hemophilia B
Among patients with hemophilia B, the number of exposure to FFP
were ranged from < 10 to > 40 while most were exposed to 30-39 times.
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Table 12. Number of exposure to whole Blood in severe hemophilia A
Exposure No. of patients
<5 29
5-10 5
11-15 1
>15 1
Chart 12.Number of exposure to whole blood in severe hemophilia A
Among patients with hemophilia A ,the number of exposure to whole
blood were ranged from < 5 to > 15 while most were exposed to less
than five times.
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Table 13. Number of exposure to whole Blood in severe hemophilia B
Exposure No. of patients
<5 8
5-10 6
11-15 0
>15 0
Chart 13. Number of exposure to whole blood in severe hemophilia B
Among patients with hemophilia B, the number of exposure to whole
blood were ranged from < 5to >15 while most were exposed less than
five times.
0
1
2
3
4
5
6
7
8
<5
8
6-10 11-15 >15
6
0 0
Table 14. Family history of Inhibitors in severe hemophilia A
Family history No. Of Patients
Yes 3
No 33
Chart 14. Family history of inhibitors in severe hemophilia A
Among patients with severe hemophilia A, only three patients had
family history of  inhibitors.
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Table 15. Family history of inhibitors in severe hemophilia B
Family history No. Of Patients
Yes 1
No 13
Chart 15. Family history of inhibitors in severe hemophilia B
Among patients with severe hemophilia B,only one patient had family
history of inhibitors.
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Table 16. Bleeding score in severe hemophilia A
Score No. of patients
1 0
2 14
3 22
Chart 16. Bleeding score in severe hemophilia A
Among 36 patients with severe hemophilia A 22 patients had bleeding
score of 3.
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Table 17. Bleeding Score in severe hemophilia B
Score No. of patients
1 0
2 6
3 8
Chart 17. Bleeding score in severe hemophilia B
Among 14 patients with severe hemophilia B 8 patients had bleeding
score of 3.
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Table 18 .Bethesda assay of patients studied
Bethesda assay No of patients Percntage
Negative 38 76 %
High responders 10 20 %
Low responders 2 4 %
Chart 18.  Bethesda assay of patient studied
Among 50 patients studied 20 % had high responding antibody
titers, 4% had low responding antibody titers and 76% had no inhibitors.
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Table 19. Inhibitor prevalence in severe hemophilia A
Bethesda assay No of patients percentage
Negative 25 69 %
High responders 9 25 %
Low responders 2 6 %
Chart 19 . Inhibitor prevalence in severe hemophilia A
Among 36 cases of severe hemophilia A 25% had high responding
inhibitors,6 percent had low responding inhibitors and 69 % had no
inhibitors.
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Table 20 . Inhibitor prevalence in severe hemophilia B
Bethesda assay No of patients percentage
Negative 13 93 %
High responders 1 7 %
Chart 20 .  Inhibitor prevalence in severe hemophilia B
Among 14 cases of severe hemophilia B 7% had inhibitor.
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Table 21. Number of cumulative exposure days Vs Inhibitor
Cumulative
exposure days
Inhibitor
No Yes
<20 20 1
20-30 10 2
>30 8 9
Chart 21. Number of cumulative exposure days Vs Inhibitor
Inhibitor development were compared with number of cumulative
exposure days for factor replacement .Patients with more cumulative
exposure days had increased risk for inhibitor development and vice
versa. This association was statistically significant with P value of 0.002.
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Table 22. Number of exposure to cryoprecipitate Vs inhibitor
Cryoprecipitate
category
Inhibitor
No yes
<10 12 4
11-19 22 5
20-29 4 3
Chart 22. Number of exposure to cryoprecipitate Vs Inhibitor
Inhibitor developments were compared with number of exposure to
cryoprecipitate. This association was not statistically significant with P
value of 0.403.
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Table 23. Number of exposure to FFP Vs Inhibitor
FFP category
Inhibitor
No Yes
<10 4 0
11-19 11 2
20-29 14 6
30-39 8 3
40-49 1 1
Chart 23 .Number of exposure to FFP Vs Inhibitor
Inhibitor developments were compared with number of exposure to
fresh frozen plasma. This association was not statistically significant with
P value of 0.559.
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Table 24. Number of exposure to whole blood Vs Inhibitors
Whole blood category Inhibitor present
No Yes
<5 30 7
6-9 8 3
10-14 0 1
15-19 0 1
Chart 24. Number of exposure to whole blood Vs Inhibitors
Inhibitor developments were compared with number of exposure to
whole blood. This association was not statistically significant with
P value of 0.074.
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Table 25.Age at the time of study Vs inhibitor
Age Inhibitor
No Yes
0-9 5 2
10-19 14 5
20-29 7 3
30-39 8 1
40-49 2 1
50-50 1 0
60-60 1 0
Chart 25. Age at the time of study Vs inhibitor
Inhibitor developments were compared with age at the time of study.
This association was not statistically significant with P value of 0.926.
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Table 26. Age at the time of diagnosis Vs inhibitors
Age at diagnosis Inhibitor
No Yes
0-6 months 1 5
7-12 months 8 7
13-18 months 11 0
19-24 months 9 0
25-30 months 9 0
Chart 26. Age at the time of diagnosis Vs inhibitors
Inhibitor development was compared with age at the time of
diagnosis of hemophilia. Patients with early age at the time of diagnosis
had more chance for development of inhibitors and vice versa. This
association was statistically more significant with P value of 0.000.
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Table 27. Mean age of patients at the time of study Vs inhibitors
Inhibitors Mean age
No 23.63
Yes 19.33
Chart 27. Mean age of patients at the time of study Vs inhibitors
Mean age of patients at the time of study with inhibitor was 19.33yrs.
Mean age of patients at the time of study with no inhibitor was 23.63yrs.
0
5
10
15
20
25
inhibitor absent inhibitor present
23.63
19.33
inhibitor absent inhibitor present
Table 28. Mean age of patients at the time of diagnosis Vs inhibitors
Chart 28. Mean age of patients at the time of diagnosis Vs inhibitors
Mean age of patients at the time of diagnosis with inhibitor was 7.92yrs.
Mean age of patients at the time of diagnosis with no inhibitor was
25.32yrs.
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Table 29. Bleeding score vs inhibitors
Score Inhibitors
No Yes
2 20 0
3 18 12
Chart 29. Bleeding score Vs inhibitors
Inhibitor development were compared with bleeding score of the
patients. Patients with inhibitors had high bleeding score and vice versa.
This association was statistically significant with P value of 0.001.
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Table 30. Family history of inhibitor Vs inhibitor development
Family
history of
inhibitor
Inhibitors percentage
Yes No
yes 4 0 100%
no 8 38 17 %
Chart 30.Family history of inhibitor Vs inhibitor development
Inhibitor development was compared with family history of
inhibitors. Patients with family history of inhibitors had very high risk for
development of inhibitors. This association was statistically more
significant with P value of 0.000.
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DISCUSSION
Deficiency or absence of factor VIII or factor IX causes hemophilia
A and B respectively. These are congenital bleeding disorders inherited
as an X-linked recessive pattern.  Prevalence of hemophilia A and B is 1
in 5000 and 1 in 50,000 live births respectively. According to the level of
factor VIII or IX hemophilia is classified into mild (6-30 IU/dl), moderate
(1-5 IU /dl) and severe (< 1IU /dl).
The most common genetic defects associated with hemophilia is
inversion followed by deletions, duplications and frame shift mutations.
Approximately two third of patients have a family history of hemophilia.
In the remaining cases the disease occurs due to spontaneous mutations in
F8 or F9 gene.
Clinical features depend on the severity of hemophilia. Patients
with severe disease, experience spontaneous bleeding episodes since
early life. Recurrent hemarthrosis leads to joint deformity and limitation
of movement. Patients with moderate disease have rare spontaneous
bleeds but massive bleeding following trauma.  Patients with mild
hemophilia experience bleeding only after trauma or surgery.
Prolongation of activated Partial Thromboplastin Time (aPTT) is
the hallmark feature of hemophilia. Patients usually have normal platelet
count, bleeding time and prothrombin time (PT). Specific determination
of factor VIII or IX level is essential for diagnosis.
Treatment is by replacing the missing factor. Before the discovery
of recombinant factor VIII concentrates the life expectancy of hemophilia
was limited. Cryoprecipitate and Fresh Frozen Plasma can be used in the
absence of factor concentrates.
Widespread use of factor concentrates and blood products is
associated with development of complications. These include allergic
reactions and transfusion transmitted infections. Viruses like HIV,
hepatitis B, hepatitis C, parvovirus B19 and other unknown viruses are
transmitted by factor replacement. In patients treated with older less pure
products the HIV seroconversion occurs in 30-90% of patients.
Recent problem in treating patients with hemophilia is the
development of alloantibodies against factor VIII or IX, also known as
inhibitors. This should be suspected if the patient is not responding to
replacement of missing factor at therapeutic doses.
Prevalence of inhibitors in hemophilia A is 5-10% of all cases and
20% of severe cases. In patients with hemophilia B only 3-5% of patients
have the risk of developing inhibitor. Factors associated with inhibitor
development is broadly classified into,
 Patient related factors and
 Treatment  related factors
Patient related factors:
Inhibitor development is more common in patients with hemophilia
A, severe disease, with family history of inhibitors, FVIII or FIX gene
mutation, African descendants, severe bleeds, surgery, vaccinations and
possible infections.
Treatment related factors:
The risk of development of inhibitor is more for patients,
 Who receive multiple factor concentrate infusions
 Who receive episodic treatment as compared to prophylaxis
 Who receive continuous infusion as compared to intermittent
infusions.
 Risk is more with plasma derived products as compared to
recombinant products.
According to various studies done all over the world around 25-38
percent of severe hemophilia A patients have inhibitors.
In this study, we studied the prevalence of inhibitors in patients
admitted in our hospital with severe hemophilia by using Bethesda assay.
1. Prevalence of inhibitors in patients with severe hemophilia A :
In our study the prevalence of inhibitors in patients with severe
hemophilia A was 31%. Among them 25% had high responding
inhibitors and 6% had low responding inhibitors. The table shows the
prevalence of inhibitors in various studies.
S.No Study Percentage
positivity
Sample size
1. RODIN study 32% 648
2. Samantha c Gouv et al 31% 574
3. Our study 31% 36
Prevalence of inhibitors in severe hemophilia B :
In this study the prevalence of inhibitors in patients with severe
hemophilia B was 7%.Table shows the prevalence of inhibitors in various
studies.
S.No Study Percentage positivity
1. Sultan Y et al 4%
2. Our study 7%
High prevalence in our study is because of small sample size.
2. Number of cumulative exposure days with inhibitor development:
In our study, patients with more cumulative exposure days had
53% chance for inhibitor development. Table shows comparison with
other studies ,this high prevalence in our study is due to small sample
size.
S.No study percentage
1. GL Bray et al 23.9%
2. Our study 53%
3. Age at the time of diagnosis with inhibitor development:
In our study patients with early age at the time of diagnosis had high
risk for development of inhibitors and vice versa. The mean age at the
time of diagnosis of patients with inhibitor is 7.92yrs and without
inhibitor is 25.32 yrs.
4. Age at the time of study with inhibitor development:
In our study, the mean age of patients with inhibitor at the time of
study was 19.33yrs and for patients without inhibitor were 23.63 yrs.
Table shows comparison with other studies.
S.No Study Mean age of patients
With inhibitor Without inhibitor
1. Patricia Pinto et al 19.31 yrs 17.76 yrs
2. Munira Borhany et al 11.9  + 8.8yrs 17.8 + 13.6 yrs
3. Our study 19.33 yrs 23.63 yrs
5. Exposure to blood products with inhibitor development:
Exposure to blood products like cryoprecipitate, Fresh Frozen
Plasma and whole blood had no significant correlation with inhibitor
development in our study.
6. Family history of inhibitor with inhibitor development:
In this study, patients with family history of inhibitors had very
high risk for inhibitor development. Various studies have proven
significant statistical correlation of family history with inhibitors. This
may be further confirmed by doing the study in larger group of patients.
CONCLUSION
 The prevalence of inhibitors was more common in severe
hemophilia A than in severe hemophilia.
 The prevalence of inhibitors in patients with severe hemophilia A
was 31 percent. Among them 25 percent had high responding
inhibitors and 6 percent had low responding inhibitors.
 The prevalence of inhibitor in patients with severe hemophilia B
was 7 percent. Small sample size may be a reason for the high
prevalence noted in our study.
 The mean age of patients with inhibitor was 19.33yrs. and for
without inhibitor was 23.63 yrs.
 Patients with more than thirty cumulative exposure days to factor
infusions had 53 percent more risk for development of inhibitors.
 Patients with earlier age at the time of diagnosis had more risk for
development of inhibitors. The mean age of patients at the time of
diagnosis with inhibitor was 7.92yrs. and for without inhibitor was
25.32 yrs.
 Patients with family history of inhibitors had very high risk for
development of inhibitors.
 Patients with inhibitors had high bleeding score and vice versa.
SUMMARY
This study was done to detect the prevalence of inhibitors in
patients with severe hemophilia by using Bethesda assay. The study was
conducted in 50 patients with severe hemophilia admitted in our hospital.
Results from the study showed that inhibitor development were
more common in severe hemophilia A than severe hemophilia B .Patients
with more number of cumulative exposure days, earlier age at the time of
diagnosis and patients with family history of inhibitors had high risk for
development of inhibitors when compared to others. So regular screening
of  hemophilic patients for inhibitor assay is mandatory to reduce factor
wastage and thereby the cost incurred. Identifying inhibitors early and
giving appropriate treatment also reduces disability in the patients.
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PROFORMA
 Name of the patient :
 Age :
 Sex :
 Age at the time of diagnosis :
 Hemophilia type :
 Factor level :
 Family h/o inhibitor :
 Exposure history :
1. Number of cumulative exposure days for FVIII :
2. Number of cumulative exposure days for FIX :
3. Number of exposure to cryoprecipitate :
4. Number of exposure to fresh frozen plasma :
5. Number of exposure to whole blood :
 Bleeding score of the patient   :
BLEEDING SCORE:
None 0
No major or 1-3 minor* 1
1-2 major or 4-6 minor* 2
3 or more major 7 or more minor* 3
Major:
 Pain
 Effusion
 Limitation of movement
 Failure to respond within 24 hours.
Minor:
 Mild pain
 Minimal swelling
 Minimal restriction of movement
 Resolves within 24 hours of treatment.
*This is measured by the number of minor and major hemarthroses per
year.
MASTER CHART
S.No Name Ageyrs Type
Factor
level
Age  at
Diagnosis
(months)
Exp. Cry FFP WB
Family
history
Bethesda
Assay
Bleed
Score
1 Abbas 10 A <1% 9 44 6 32 3 no 19.2 3
2 Ajith Kumar 13 B <1% 24 15 9 10 3 no 0 2
3 Akshay 17 A <1% 15 19 13 29 3 no 0 3
4 Anandakumar 17 B <1% 36 17 11 15 5 no 0 3
5 Aravind 9 B <1% 12 9 5 7 0 no 0 3
6 Arun Kumar 13 A <1% 6 31 9 23 3 Yes 8 3
7 Babu 37 A <1% 24 24 21 32 5 no 0 2
8 Balaji 18 A <1% 6 47 10 18 18 no 1000 3
9 Balasubramani 47 A <1% 24 18 21 33 2 no 0 2
10 Bommaiya 22 B <1% 36 19 12 20 7 no 0 2
11 Dinesh Kumar 16 A <1% 15 15 19 35 5 no 0 2
12 Gokul 12 A <1% 12 13 6 15 5 no 0 2
13 Gokulapriyan 17 A <1% 15 34 16 22 2 no 0 3
14 Jana S. Mukesh 10 B <1% 12 10 7 7 2 no 0 3
15 Jayaraman 50 A <1% 48 17 25 34 0 no 0 2
16 Joseph 64 A <1% 60 11 27 49 8 no 0 2
17 Kannan 48 B <1% 12 45 21 34 9 Yes 511 3
18 Karthik 29 A <1% 11 29 18 27 3 no 7 3
19 Karthik Kumar 30 A <1% 24 25 14 35 7 no 0 2
20 Karthik Kumar 30 A <1% 24 32 15 24 0 no 0 3
21 Kishore Raj 11 A <1% 8 36 9 25 8 no 12 3
22 Laksith 7 A <1% 5 29 23 45 6 no 15 3
23 Manikandan 10 A <1% 12 24 4 17 3 no 0 2
24 Manikandan 37 B <1% 60 30 16 27 8 no 0 3
25 Mohan Prasad 15 A <1% 18 24 12 19 1 no 0 2
26 Mohd. Aashif 17 A <1% 18 35 10 17 1 no 0 2
27 Mohd. Sultan 25 A <1% 18 25 16 30 5 no 0 3
28 Murugesan 35 B <1% 48 25 15 22 7 no 0 3
29 Naresh 20 A <1% 18 14 9 21 5 no 0 3
30 Nirmal 21 A <1% 9 32 13 21 3 no 8 3
31 Pandiraj 33 A <1% 5 49 20 36 2 Yes 19.2 3
32 Rahul Bharath 23 A <1% 18 21 11 24 4 no 0 2
33 Ramasamy 47 A <1% 48 26 26 38 0 no 0 2
34 Ramesh 39 B <1% 72 32 17 29 8 no 0 3
35 Ramkumar 22 A <1% 24 39 14 21 0 no 0 2
36 Ravikuar 17 A <1% 15 16 17 31 3 no 0 3
37 RohithVignesh 10 B <1% 18 12 9 9 2 no 0 2
38 Sanjay 10 A <1% 12 18 5 14 2 no 0 3
39 Sathish 22 A <1% 12 35 12 27 1 no 0 3
40 Senthan 7 B <1% 6 6 2 5 0 no 0 2
41 Sivakumar 26 A <1% 9 18 15 22 12 no 1.75 3
42 Sivashankar 12 A <1% 15 32 8 15 0 no 0 3
43 Sivashanmugam 18 B <1% 36 18 12 17 5 no 0 2
44 Subramani 25 A <1% 18 15 12 15 4 no 0 3
45 Surender 9 A <1% 12 28 10 21 1 no 0 2
46 Thirugnanasambandan 37 B <1% 48 27 15 25 7 no 0 3
47 Venkateswaran 35 A <1% 11 13 19 25 6 no 0 3
48 Vetrivel 3 A <1% 10 31 5 12 0 Yes 12 3
49 Ganesh 15 B <1% 24 17 10 12 5 no 0 2
50 Yuvesh 13 A <1% 5 24 10 25 4 no 3.1 3
KEY TO MASTER CHART:
S.No : Serial Number
Type : Type of hemophilia
Exp : Cumulative Exposure days for Factor concentrate Transfusion
Cry : Cryoprecipitate
FFP : Fresh frozen Plasma
WB : Whole Blood
INFORMED CONSENT
Department of General Medicine
COIMBATORE MEDICAL COLLEGE, COIMBATORE
Principal Investigator: Dr.C.Govindaraju
Research Guide: Dr.S.Usha.M.D
Organization Department of General Medicine
Informed consent: I have been invited to participate in research project titled
“PREVALENCE 0F INHIBITORS IN PATIENTS WITH HEMOPHILIA
TREATED WITH FACTOR VIII OR IX TRANSFUSION IN
COIMBATORE MEDICAL COLLEGE HOSPITAL”
I understand, I will be answering a set of questionnaire, undergo physical
examination, investigation and appropriate treatment
I also give consent to utilize my personal details for study purpose and
can be contacted if necessary
I am aware that I have the right to withdraw at any time which will not
affect my medical care
Name of the participant:
Signature:
Date:
xg;g[jy; gotk;
bgah; :
ghypdk; :
Kfthp : taJ :
muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;JtJiwapy; gl;l nkw;gog;g[
gapYk; khzth; rp.nfhtpe;juh$% mth;fs; nkw;bfhs;Sk; "nfhaKj;J}h;
kUj;Jtf; fy;Y}hp kUj;Jtkidapy; ,uj;j ciwt[ jd;ik Fiwe;jpUf;Fk;
(QPnkhgpypah A & B) nehahspfspy; fhuzpfs; 8 kw;Wk; 9 brYj;Jtjpdhy;
cUthFk; jLg;ghd;fspd; gutiyg; gw;wpa" Ma;tpy; bra;Kiw kw;Wk;
midj;J tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis
bjspt[gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;.
ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; fye;J
bfhs;s rk;kjpf;fpnwd;.
,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; ghJfhf;fg;gLtJld;
,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy;  Ml;nrgid ,y;iy vd;gij
bjhptpj;Jf;bfhs;fpnwd;. ve;j neuj;jpy; me;j Ma;tpypUe;J ehd; tpyfpf;
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;.
,lk; : ifbahg;gk; / nuif
ehs; :
